Slides

  2. Home
  3. Content Type
  4. Slides
  5. Online
Page 3 of 3
Results 151 - 214 of 214
9840-0003
Optimizing Management of IPF
9837-roosevelt
How Would You Manage President Theodore Roosevelt’s Asthma Today?
9815-eugene
Eugene’s U(I)P-Hill Battle
No image set
Updates in Atopic Dermatitis: The Allergist’s Guide to Optimizing Care - Child
9815-mary
Is Mary’s PAH Making You Dizzy?
9815-jeff
Jeff’s COPD is No Smoke!
9815-chuck
Clearing the Air on Chuck’s Asthma
9815-jane
Shedding Light on Jane’s ILD Diagnosis
9815-palliative
When Should You Consider Palliative Care in the Patient Journey?
9815-sandra
What is Your Treatment Recommendation for Sandra’s CTEPH?
9815-tracy
Tracy Has Chest Palpitations and Cough: What Does Her Imaging Tell Us?
9916-cc-cme
2019 Summer Pulmonary Updates: The Experts Weigh In
med-doc-aatd
A Closer Look at Alpha-1 Antitrypsin Deficiency: Peggy’s Story
med-doc-ph
How Pulmonary Arterial Hypertension Has Changed Iain’s Life
hopa-icon8
Biosimilars: Applying the Science to Hematology/Oncology Practice
atopic-derm2 copy
Atopic Dermatitis: Recent and Emerging Therapies
atopic-derm1
An Introduction to Atopic Dermatitis
pah icon
PAH Today: Mastering Current, Tailored Treatment
No image set
Achieving Better Control of Severe Asthma
asthma-uncontrol icon
A Personalized Approach to Managing Uncontrolled Asthma
biosims-archmed icon23
Top Questions about Biosimilars in Dermatology
biosims-archmed icon1
Top Questions about Biosimilars in Gastroenterology
biosims-archmed icon2
Top Questions about Biosimilars in Rheumatology
biosims-archmed icon
Top Questions about Biosimilars in Hematology/Oncology
biosims-gastro2
Biosimilars and Patients with Inflammatory Bowel Disease
biosims-gastro1
Biosimilars: The New Era of Gastroenterology Management Considerations
psoriasis-nurse
Psoriasis Management Considerations: What Would You Do?
psoriasis-case3
Jamie Develops Complications with Her Psoriasis
psoriasis-case2
Psoriasis: Three Case Studies in the Primary Care Setting
psoriasis-case1
Cindy Has a Complex Case of Psoriasis
9707-ella
Famous People with Diabetes: Ella Fitzgerald
9707-jerry
Famous People with Diabetes: Jerry Garcia
aims icon-target
Targeting B-cells in Primary Progressive MS (PPMS)
aims icon-comorb
Comorbidities and Selection of DMTs
aims icon-gut
The Gut Microbiota in MS
aims icon-early
Early MS: Induction Therapy and Escalation Strategies
aims icon-vitamin
Vitamin D: Modifiable Risk Factor and its Role in the Management of Patients with MS
t2diabetes-slides1
Download Slides: Optimizing Diabetes Treatment in a Sea of Treatment Options
t2diabetes-slides2
Download Slides: Advancing T2DM Therapy with Confidence
t2diabetes-louise
Getting to Goal Can Be Difficult: Louise
t2diabetes-brian
Getting to Goal Can Be Difficult: Brian
IL-rheum-case3
Considering Biosimilars in Patients Failing their Initial Biologic
IL-rheum-case2
When to Switch? Biologically Experienced Patients with Spondyloarthritis
IL-rheum-case1
Innovator or Biosimilar for a Patient with Rheumatoid Arthritis
IL-gastro-case3
Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?
IL-gastro-case2
Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic
IL-gastro-case1
Innovator or Biosimilar for a Patient with Ulcerative Colitis?
IL-derm-case3
Switching Between Biologics: Is a Biosimilar an Option?
IL-derm-case2
When to Switch? Biologically Experienced Psoriasis Patients
IL-derm-case1
Innovator or Biosimilar for a Patient with Psoriasis
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
IL-fund-case1
What is a Biologic?
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-green5
Are You Ready to Use Biosimilars in Your Practice?
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
biosims-full5
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
biosims-green8
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
biosims-full7
Biosimilars: As Safe and Effective as the Reference Product?
biosims-green
Drift and the Manufacturing of Biologics: What is it and Does it Matter?
biosims-full8
Biosimilars in Clinical Practice: Interchangeability and Extrapolation
No image set
Addressing Common Barriers to Adherence
Page 3 of 3

Search